SLC6A4 and Prader-Willi syndrome: We hypothesized that receptor and transporter expression may be associated with serum levels of DA and 5-HT in patients, and 5-HT2A and SERT expression in PBMCs may be potential treatment response biomarkers for clinical follow-up of risperidone-treated PWS.